SELLAS Approaches Phase 3 REGAL Milestone: Final Data Readout Near on GPS in Acute Myeloid Leukemia
SELLAS Life Sciences is on the verge of a major milestone as its pivotal Phase 3 REGAL trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML) nears completion, with only two events remaining before the locked, blinded analysis and subsequent data revelation. The company expects this readout to be transformational for both investors and the AML clinical landscape.
Cash Position Remains Robust—Over $114 Million as Pipeline Progresses
SELLAS reported a strong financial position to power its clinical efforts. As of March 31, 2026, the company held $107.1 million in cash and cash equivalents, bolstered by an additional $7.5 million from warrant exercises in the second quarter, pushing total cash over $114 million. No shares have been sold yet under the $150 million at-the-market (ATM) facility, leaving the company with ample flexibility for future funding without immediate shareholder dilution.
| Key Balance Sheet Metrics | Q1 2026 | Q4 2025 |
|---|---|---|
| Cash & Cash Equivalents ($M) | 107.10 | 71.79 |
| Total Assets ($M) | 114.18 | 78.35 |
| Total Liabilities ($M) | 6.77 | 7.47 |
| Total Stockholders' Equity ($M) | 107.41 | 70.87 |
Clinical Pipeline Accelerates: SLS009 Enters Phase 2 in High-Risk AML Patients
Alongside the REGAL trial progress, SELLAS initiated a Phase 2 study of SLS009 (tambiciclib) in newly diagnosed, first-line AML patients—including those unlikely to respond to standard AZA/VEN therapies. SLS009, a next-generation CDK9 inhibitor, demonstrated encouraging preclinical results presented at the 2026 AACR meeting, notably driving cell death in AML models with high-risk genetic mutations (TP53, ASXL1) that typically predict poor outcomes.
Topline results for the SLS009 trial are anticipated in Q4 2026, with high hopes that this differentiated compound could reshape treatment expectations for patients traditionally underserved by current standards.
Expenses Reflect Advancement and Preparation for Regulatory Filings
Investment in research and development ramped up to $5.13 million for Q1 2026 from $3.21 million a year prior, reflecting intensified clinical activity and preparations for a possible Biologics License Application. General and administrative expenses increased to $4.12 million from $2.86 million year-over-year, driven by higher professional, consulting, and public company costs.
| Operating Metric (in $ thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Research & Development | 5,129 | 3,205 |
| General & Administrative | 4,123 | 2,858 |
| Net Loss | 8,407 | 5,813 |
| Net Loss per Share (basic/diluted) | 0.05 | 0.07 |
| Shares Outstanding (basic/diluted) | 172,481,541 | 87,760,320 |
Strong Pipeline and Financial Foundation Set Stage for Major Near-Term Catalysts
With only two more events to trigger the closely-watched REGAL trial data and the Phase 2 SLS009 study now dosing high-risk AML patients, SELLAS is positioned for potential breakthroughs in both clinical and corporate arenas. The company’s solid cash position, strengthened by recent warrant exercises and unused ATM facility, allows management to advance these programs with confidence.
As SELLAS approaches momentous clinical milestones, investors and cancer specialists alike may want to keep a close eye. The impending data releases could meaningfully impact prospects for both patients and the company’s long-term trajectory.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI